| Methods |
Method of random allocation not stated. No placebo use or blinding of outcome assessments |
| Participants |
75 women with vaginal delivery in Colombia. Exclusion criteria: asthma, coagulopathy, twins, stillbirth, lacerations, and "amniotic fluid in the blood collection". |
| Interventions |
Misoprostol 50 mcg sublingually after cord clamp vs oxytocin 16 m IU per minute intravenously after cord clamp vs methylergometrine 0.2 mg after placenta delivery. |
| Outcomes |
Blood loss, side‐effects, cost.
Method of collection or estimation of blood loss not stated. |
| Notes |
Management of third stage: no mention of third stage management technique.
No reported postrandomisation exclusions or loss to follow‐up. Analysis was based on the total population of 75 women. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Unclear risk |
Method of random allocation not stated. |
| Allocation concealment (selection bias) |
Unclear risk |
No mention of how the concealment occurred. |
| Blinding (performance bias and detection bias)
All outcomes |
High risk |
No placebo use or blinding of outcome assessments. |
| Incomplete outcome data (attrition bias)
All outcomes |
Low risk |
No loss to follow‐up and postrandomisation exclusions have been reported. |
| Selective reporting (reporting bias) |
Low risk |
Primary outcomes of the review have been reported. |
| Other bias |
Low risk |
The characteristics of the 2 groups have been comparable. |
